International consensus diagnostic criteria for neuromyelitis optica spectrum disordersDean M. Wingerchuk, Brian G. Weinshenker, Brenda Banwell et al.|Neurology|2015Cited by 4.6k
Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trialBruce Cree, Eliezer Katz, Jeffrey L. Bennett et al.|The Lancet|2019Cited by 722
Myelin-oligodendrocyte glycoprotein antibody-associated diseaseRomain Marignier, Bernhard Hemmer, Yael Hacohen et al.|The Lancet Neurology|2021Cited by 518
Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trialAnthony Traboulsee, Brian G. Weinshenker, Benjamin Greenberg et al.|The Lancet Neurology|2020Cited by 495
Myelin Oligodendrocyte Glycoprotein Antibody–Positive Optic Neuritis: Clinical Characteristics, Radiologic Clues, and OutcomeJohn J. Chen, Sean J. Pittock, Eoin P. Flanagan et al.|American Journal of Ophthalmology|2018Cited by 402